Cannabinoid WIN-55,212-2

Medical Marijuana in the treatment of Multiple Sclerosis.
Post Reply
User avatar
Petr75
Family Elder
Posts: 782
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Cannabinoid WIN-55,212-2

Post by Petr75 » Tue Jan 21, 2020 8:05 am

2020 Jan 17
Department of Psychiatry and Psychotherapy, University of Göttingen and Center Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), Göttingen, Germany
Dose-dependent effect of cannabinoid WIN-55,212-2 on myelin repair following a demyelinating insult
https://www.ncbi.nlm.nih.gov/pubmed/31953431

Abstract
Dysfunctions in the endocannabinoid system have been associated with experimental animal models and multiple sclerosis patients. Interestingly, the endocannabinoid system has been reported to confer neuroprotection against demyelination. The present study aims to assess the effects of the cannabinoid agonist WIN-55,212-2 in cuprizone fed animals on myelin repair capacity. Animals exposed to cuprizone were simultaneously treated withWIN-55,212-2, behaviorally tested and finally the corpus callosum was exhaustively studied by Western blotting, qRT-PCR and a myelin staining procedure. We report that the long-term administration of WIN-55,212-2 reduced the global amount of CB1 protein. Histological analysis revealed clear demyelination after being fed cuprizone for three weeks. However, cuprizone-fed mice subjected to 0.5 mg/Kg of WIN-55,212-2 displayed no differences when compared to controls during demyelination, although there was a robust increase in the myelinated axons during the remyelination phase. These animals displayed better performance on contextual fear conditioning which was in turn non-attributable to an antinociceptive effect. In contrast, a 1 mg/Kg dosage caused a remarkable demyelination accompanied by limited potential for myelin repair. Upon drug administration while mice ongoing demyeliniation, the expression of Aif1 (microglia) and Gfap (astrocytes) followed a dose-dependent manner whereas the expression of both markers was apparently attenuated during remyelination. Treatment with vehicle or 0.5 mg/Kg of the drug during demyelination increased the expression of Pdgfra (oligodendrocyte precursor cells) but this did not occur when 1 mg/Kg was administered. In conclusion, the drug at 0.5 mg/Kg did not alter myelin architecture while 1 mg/Kg had a deleterious effect in this model.

oliviamas
Newbie
Posts: 2
Joined: Mon Feb 24, 2020 5:37 am

Re: Cannabinoid WIN-55,212-2

Post by oliviamas » Tue Feb 25, 2020 5:58 am

Very interesting article. I have chronic back pain and CBD flowers from https://berkshirecbd.com/shop/ help me with my problems.

Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Medical Marijuana”